1. |
Andreas S, Konstantinos A, Stamatios L. Brain natriuretic peptide in cardiovascular diseases. Am J Med Sci,2008,335:477-483.
|
2. |
Andrew D, Michaels AD, Jee KC, et al. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Cardiac Failure,2005,11:425-431.
|
3. |
Yap LB, Ashrafian H, Mukerjee D, et al. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem,2004,37:847-856.
|
4. |
Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab,1993,76:91-96.
|
5. |
Cargill RI, Lipworth BJ. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest,1996,110:1220-1225.
|
6. |
Bhat G, Costea A. Reversibility of medically unresponsive pulmonary hypertension with nesiritide in a cardiac transplant recipient. ASAIO J,2003,49:608-610.
|
7. |
Daniel J, Lenihan Mary T, Vooletich J, et al. Nesiritide may be valuable in the evaluation and treatment of secondary pulmonary hypertension. J Card Fail,2005,11(6 Suppl):S159.
|
8. |
Chen T, Jiang N, Wang L, et al. The significance of natriuretic peptide in treatment of pulmonary hypertension after mitral valve replacement. J Thorac Cardiovasc Surg,2014,147:1362-1367.
|
9. |
Michaels AD, Chatterjee K, De Marco T. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail,2005,11:425-431.
|
10. |
Klinger JR, Thaker S, Houtchens J, et al. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest,2006,129:417-425.
|
11. |
Khush KK, De Marco T, Vakharia KT, et al. Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension. J Card Fail,2006,12:507-513.
|
12. |
Stevens TL, Burnett JC Jr, Kinoshita M, et al. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest,1995,95:1101-1108.
|
13. |
Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation,2005,111:1487-1491.
|
14. |
Chen HH, Lainchbury JG, Harty GJ, et al. Maximizing the natriuretic peptide system in experimental heart failure:subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation,2002,105:999-1003.
|
15. |
Klinger JR, Petit RD, Warburton RR, et al. Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats. J Appl Physiol,1993,75:1615-1623.
|